---
title: "EVERJOY HEALTH released its 2024 annual performance, turning from profit to a loss of 147 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/229894279.md"
description: "EVERJOY HEALTH released its 2024 annual performance report, with operating revenue of 1.204 billion yuan, a year-on-year decrease of 5.79%. The net loss attributable to shareholders of the listed company was 147 million yuan, and the net loss after deducting non-recurring gains and losses was 168 million yuan, a year-on-year increase of 42.12%. The basic loss per share was 0.1595 yuan. The operating revenue of the building materials business was 1.016 billion yuan, a year-on-year decrease of 7.20%"
datetime: "2025-02-27T10:20:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/229894279.md)
  - [en](https://longbridge.com/en/news/229894279.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/229894279.md)
generator: "portal-rs"
---

# EVERJOY HEALTH released its 2024 annual performance, turning from profit to a loss of 147 million yuan

According to the Zhitong Finance APP, EVERJOY HEALTH (002162.SZ) released its annual report for 2024, reporting an operating income of 1.204 billion yuan, a year-on-year decrease of 5.79%. The net loss attributable to shareholders of the listed company was 147 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 168 million yuan, a year-on-year increase of 42.12%. The basic loss per share was 0.1595 yuan. During the reporting period, the company's building materials business generated an operating income of 1.016 billion yuan, a year-on-year decrease of 7.20%, which is in line with the overall industry situation

### Related Stocks

- [002162.CN](https://longbridge.com/en/quote/002162.CN.md)

## Related News & Research

- [Nasdaq Futures Plunge as Rising Bond Yields Drive Chip Selloff](https://longbridge.com/en/news/296216952.md)
- [Frozen blueberries recall categorized under FDA's highest Class I risk level](https://longbridge.com/en/news/296506599.md)
- [BUZZ-Faeth Therapeutics rises after FDA grants fast-track status for cancer drug](https://longbridge.com/en/news/296104768.md)
- [TempraMed Announces Extension of Maccabi Healthcare Services Agreement | TMPTF Stock News](https://longbridge.com/en/news/296479419.md)
- [Realheart targets February 2028 readiness for first-in-human implant of total artificial heart](https://longbridge.com/en/news/296444895.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**